IL143946A0 - Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications - Google Patents
Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indicationsInfo
- Publication number
- IL143946A0 IL143946A0 IL14394699A IL14394699A IL143946A0 IL 143946 A0 IL143946 A0 IL 143946A0 IL 14394699 A IL14394699 A IL 14394699A IL 14394699 A IL14394699 A IL 14394699A IL 143946 A0 IL143946 A0 IL 143946A0
- Authority
- IL
- Israel
- Prior art keywords
- combinations
- bile acid
- transfer protein
- cholesteryl ester
- acid transport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11395598P | 1998-12-23 | 1998-12-23 | |
US14304799P | 1999-07-07 | 1999-07-07 | |
PCT/US1999/027947 WO2000038726A1 (en) | 1998-12-23 | 1999-12-17 | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications |
Publications (1)
Publication Number | Publication Date |
---|---|
IL143946A0 true IL143946A0 (en) | 2002-04-21 |
Family
ID=26811682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14394699A IL143946A0 (en) | 1998-12-23 | 1999-12-17 | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications |
Country Status (23)
Country | Link |
---|---|
US (2) | US6458851B1 (xx) |
EP (2) | EP1342475A1 (xx) |
JP (1) | JP2002533412A (xx) |
KR (1) | KR20010108046A (xx) |
CN (1) | CN1342089A (xx) |
AT (1) | ATE241386T1 (xx) |
AU (1) | AU776620B2 (xx) |
BR (1) | BR9916486A (xx) |
CA (1) | CA2356422C (xx) |
CZ (1) | CZ20012340A3 (xx) |
DE (1) | DE69908414T2 (xx) |
DK (1) | DK1140188T3 (xx) |
EA (1) | EA005815B1 (xx) |
ES (1) | ES2200587T3 (xx) |
HK (2) | HK1041443A1 (xx) |
HU (1) | HUP0201972A3 (xx) |
IL (1) | IL143946A0 (xx) |
MX (1) | MXPA01006471A (xx) |
NO (1) | NO20013161L (xx) |
NZ (1) | NZ512536A (xx) |
PL (1) | PL348508A1 (xx) |
PT (1) | PT1140188E (xx) |
WO (1) | WO2000038726A1 (xx) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA005815B1 (ru) * | 1998-12-23 | 2005-06-30 | Джи.Ди.Сирл Ллс | Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний |
EP1182195A4 (en) * | 1999-05-07 | 2003-03-26 | Takeda Chemical Industries Ltd | CYCLIC CONNECTIONS AND APPLICATIONS THEREOF |
SE0000772D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | Chemical compounds |
EG26979A (en) | 2000-12-21 | 2015-03-01 | Astrazeneca Ab | Chemical compounds |
GB0121337D0 (en) | 2001-09-04 | 2001-10-24 | Astrazeneca Ab | Chemical compounds |
GB0121621D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
GB0121622D0 (en) | 2001-09-07 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
CN1582151A (zh) | 2001-09-08 | 2005-02-16 | 阿斯特拉曾尼卡有限公司 | 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物 |
CA2466081A1 (en) * | 2001-11-09 | 2003-05-15 | Atherogenics, Inc. | Methods of reversing and preventing cardiovascular pathologies |
JP2005518408A (ja) * | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用 |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
GB0213669D0 (en) | 2002-06-14 | 2002-07-24 | Astrazeneca Ab | Chemical compounds |
GB0304194D0 (en) | 2003-02-25 | 2003-03-26 | Astrazeneca Ab | Chemical compounds |
GB0307918D0 (en) | 2003-04-05 | 2003-05-14 | Astrazeneca Ab | Therapeutic use |
CN1886124A (zh) | 2003-09-26 | 2006-12-27 | 日本烟草产业株式会社 | 抑制残余脂蛋白产生的方法 |
EP2927693A1 (en) | 2004-10-06 | 2015-10-07 | The Brigham and Women's Hospital | Relevance of achieved levels of markers of systemic inflammation following treatment |
US20060257450A1 (en) * | 2005-03-21 | 2006-11-16 | Sreenivasu Mudumba | Drug delivery systems for treatment of diseases or conditions |
BRPI0608152A2 (pt) * | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
WO2007092620A2 (en) * | 2006-02-09 | 2007-08-16 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
PL2001466T3 (pl) | 2006-03-23 | 2016-06-30 | Santen Pharmaceutical Co Ltd | Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń |
WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
WO2011150286A2 (en) | 2010-05-26 | 2011-12-01 | Satiogen Pharmaceuticals,Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
CN103228270B (zh) | 2010-11-08 | 2016-02-10 | 阿尔比里奥公司 | 含ibat抑制剂和胆汁酸结合剂的药物组合 |
MX338535B (es) | 2010-11-08 | 2016-04-21 | Albireo Ab | Inhibidores de ibat para el tratamiento de enfermeades hepaticas. |
JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
EP3266457A1 (en) | 2011-10-28 | 2018-01-10 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
EP3278796A1 (en) | 2011-10-28 | 2018-02-07 | Lumena Pharmaceuticals LLC | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
BR112015023646A2 (pt) | 2013-03-15 | 2017-07-18 | Lumena Pharmaceuticals Inc | inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino |
CN105228615A (zh) | 2013-03-15 | 2016-01-06 | 鲁美纳医药公司 | 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂 |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
WO2015195748A2 (en) | 2014-06-17 | 2015-12-23 | Ganiban Gary | Devices and methods to provide hands free scleral depression during ophthalmic procedures |
KR20220082931A (ko) | 2014-06-25 | 2022-06-17 | 이에이 파마 가부시키가이샤 | 고형 제제 및 그의 착색 방지 또는 착색 감소 방법 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN108601745B (zh) | 2016-02-09 | 2021-12-07 | 阿尔比里奥公司 | 口服考来烯胺制剂及其用途 |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
JP6954926B2 (ja) | 2016-02-09 | 2021-10-27 | アルビレオ・アクチボラグ | 経口コレスチラミン製剤及びその使用 |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
JP7328207B2 (ja) | 2017-08-09 | 2023-08-16 | アルビレオ・アクチボラグ | コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用 |
CA3071285A1 (en) | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
WO2019234077A1 (en) | 2018-06-05 | 2019-12-12 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
AU2019290337B2 (en) | 2018-06-20 | 2023-01-12 | Albireo Ab | Crystal modifications of odevixibat |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
CN113453753A (zh) | 2019-02-06 | 2021-09-28 | 阿尔比里奥公司 | 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途 |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
PL3921028T3 (pl) | 2019-02-06 | 2023-02-13 | Albireo Ab | Związki benzotiadiazepinowe i ich zastosowanie jako modulatory kwasów żółciowych |
CN114072153A (zh) | 2019-02-12 | 2022-02-18 | 米鲁姆制药公司 | 用于治疗胆汁淤积的方法 |
TW202134222A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途 |
CA3158276A1 (en) | 2019-12-04 | 2021-06-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
CR20220315A (es) | 2019-12-04 | 2022-10-26 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar |
AR120679A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
CN114761018A (zh) | 2019-12-04 | 2022-07-15 | 阿尔比里奥公司 | 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途 |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
TW202134221A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 |
AR120674A1 (es) | 2019-12-04 | 2022-03-09 | Albireo Ab | Compuestos de benzotiazepina y su uso como ácido biliar |
TW202134220A (zh) | 2019-12-04 | 2021-09-16 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途 |
EP4188541A1 (en) | 2020-08-03 | 2023-06-07 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
JP2023549226A (ja) | 2020-11-12 | 2023-11-22 | アルビレオ エービー | 進行性家族性肝内胆汁うっ滞症(pfic)を処置するためのオデビキシバット |
BR112023010799A2 (pt) | 2020-12-04 | 2023-10-03 | Albireo Ab | Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares |
US20230398125A1 (en) | 2022-06-09 | 2023-12-14 | Albireo Ab | Treating hepatitis |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB860303A (en) | 1958-06-20 | 1961-02-01 | Ici Ltd | Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª |
US3253157A (en) | 1963-02-08 | 1966-05-24 | Robotron Corp | Timing circuit for actuating a load in accurate relationship to two inputs |
US3389144A (en) | 1965-06-08 | 1968-06-18 | Mcneilab Inc | 5-pyridyl-2, 3, 4, 5-tetrahydrobenzothiepin-5-ols |
US3287370A (en) | 1965-06-08 | 1966-11-22 | Mcneilab Inc | Tetrahydrobenzothiepins |
DE1593760A1 (de) | 1967-02-01 | 1972-06-08 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung neuer Benz-epinderivate |
US3444176A (en) | 1967-04-28 | 1969-05-13 | Mcneilab Inc | Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4058552A (en) | 1969-01-31 | 1977-11-15 | Orchimed Sa | Esters of p-carbonylphenoxy-isobutyric acids |
FR2077733B1 (xx) | 1970-02-10 | 1973-03-16 | Roussel Uclaf | |
US3694446A (en) | 1970-02-24 | 1972-09-26 | William J Houlihan | 5-(substituted-benzyl)-benzocycloheptenes and-1-benzthiepines |
US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
DE2230383C3 (de) | 1971-10-01 | 1981-12-03 | Boehringer Mannheim Gmbh, 6800 Mannheim | Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben |
US4002750A (en) | 1972-04-28 | 1977-01-11 | Carlo Erba S.P.A. | Pyrazine 4-oxide derivatives and process for their preparation |
US3948973A (en) | 1972-08-29 | 1976-04-06 | Sterling Drug Inc. | Halocyclopropyl substituted phenoxyalkanoic acids |
US3962261A (en) | 1974-02-04 | 1976-06-08 | Warner-Lambert Company | 2,3,4,5-tetra hydro-5-oxo-1-benzothiepi n-4-carboxamide 1,1-dioxides |
FR2260569B1 (xx) | 1974-02-08 | 1978-06-16 | Ugine Kuhlmann | |
JPS5612114B2 (xx) | 1974-06-07 | 1981-03-18 | ||
SE420725B (sv) | 1974-09-26 | 1981-10-26 | Ciba Geigy Ag | Sett att framstella 2,3-dihydro-1-benstiepin-4-karboxylsyraamider |
DE2739689C2 (de) | 1977-09-02 | 1986-10-16 | Euratom | Thermische Wärmepumpe |
US4251526A (en) | 1977-10-31 | 1981-02-17 | Mccall John M | 2-Benzothiepins and compositions and methods of use therefore |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
DE2928096A1 (de) | 1979-07-12 | 1981-02-05 | Basf Ag | Magnetischer aufzeichnungstraeger |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
AU548996B2 (en) | 1980-02-04 | 1986-01-09 | Merck & Co., Inc. | Tetrahydro-2h-pyran-2-one derivatives |
DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
AU548253B2 (en) | 1981-05-11 | 1985-12-05 | Pierre Fabre S.A. | Benzoxepine derivatives and sulphur and nitrogen analogues thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
FI77669C (fi) | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
EP0244364A3 (en) | 1986-04-30 | 1992-04-01 | Sandoz Ag | Preparation of olefinic compounds |
AU597671B2 (en) | 1986-06-20 | 1990-06-07 | Suntory Limited | 2-Phenylbenzoxepin derivative |
WO1989001477A1 (en) | 1987-08-19 | 1989-02-23 | E.I. Du Pont De Nemours And Company | Process for preparing sulfonylurea salts |
DE3835291A1 (de) | 1988-04-19 | 1989-11-02 | Bayer Ag | 1,3-disubstituierte pyrrolidine |
US5158943A (en) | 1988-11-21 | 1992-10-27 | Takeda Chemical Industries, Ltd. | Sulfur-containing heterocyclic compounds |
DE3901527A1 (de) | 1989-01-20 | 1990-07-26 | Hoechst Ag | Alkylierte polyethyleniminderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel sowie pharmazeutische praeparate |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
DE3930696A1 (de) | 1989-09-14 | 1991-03-28 | Hoechst Ag | Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel |
US5075293A (en) | 1989-10-10 | 1991-12-24 | The Dow Chemical Company | ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides |
US5153184A (en) | 1989-10-10 | 1992-10-06 | Dowelanco | ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides |
GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
FR2661676A1 (fr) | 1990-05-02 | 1991-11-08 | Lipha | Derives d'amino benzocycloalcanes, procedes de preparation et medicaments les contenant. |
WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
EP0583346A1 (en) | 1991-04-12 | 1994-02-23 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
AU1532492A (en) | 1991-04-18 | 1992-11-17 | Dr. Lo Zambeletti S.P.A. | Use of heterocyclic compounds for the treatment of inflammatory pain |
JP2708633B2 (ja) | 1991-05-03 | 1998-02-04 | ライシオン テータート オサケユイチア アクティエボラーグ | 血清における高コレステロールレベルを低めるための物質及びその物質を調製するための方法 |
US5334600A (en) | 1991-07-30 | 1994-08-02 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
US5260316A (en) | 1991-07-30 | 1993-11-09 | Ciba-Geigy Corporation | Isoquinolyl substituted hydroxylamine derivatives |
DE69224115T2 (de) | 1991-07-30 | 1998-08-20 | Ciba Geigy Ag | Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren |
US5350761A (en) | 1991-07-30 | 1994-09-27 | Ciba-Geigy Corporation | Indolyl substituted hydroxylamine derivatives |
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
EP0534316A1 (de) | 1991-09-21 | 1993-03-31 | Hoechst Aktiengesellschaft | Verwendung von alkylierten Polyethyleniminderivaten zur Anreicherung von Gallensäuren |
US5519001A (en) | 1991-12-19 | 1996-05-21 | Southwest Foundation For Biomedical Research | CETP inhibitor polypeptide antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
ATE135380T1 (de) | 1991-12-20 | 1996-03-15 | Hoechst Ag | Polymere und oligomere von gallensäurederivaten, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
NZ245504A (en) | 1991-12-20 | 1995-08-28 | Hoechst Ag | Bile acid derivatives containing an ethylenically unsaturated grouping |
ATE180968T1 (de) | 1991-12-20 | 1999-06-15 | Hoechst Ag | Polyaspartamidderivate als adsorptionsmittel für gallensäuren, mit gallensäuren beladene polyaspartamidderivate und verfahren zu deren herstellung sowie deren anwendung als arzneimittel |
US5244887A (en) | 1992-02-14 | 1993-09-14 | Straub Carl D | Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof |
GB9203347D0 (en) | 1992-02-17 | 1992-04-01 | Wellcome Found | Hypolipidaemic compounds |
ATE201442T1 (de) | 1992-02-29 | 2001-06-15 | Aventis Res & Tech Gmbh & Co | Komplexe enthaltend glykosyl-phosphatidylinositol-proteine und cholansäurederivate, verfahren zu ihrer herstellung und ihre verwendung |
ES2080549T3 (es) | 1992-03-28 | 1996-02-01 | Hoechst Ag | Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo. |
DK0637297T3 (da) | 1992-04-22 | 2000-09-18 | Ligand Pharm Inc | Forbindelser, der har selektivitet til retinoid-X-receptorer |
CA2093577C (en) | 1992-05-07 | 2006-01-03 | Michael Klaus | Alkyl or alkoxy substituted s-heterocyclic retinoids |
FR2698873B1 (fr) | 1992-12-07 | 1995-02-24 | Lipha | Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant. |
IL108633A (en) | 1993-02-15 | 1998-07-15 | Wellcome Found | History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them |
IL108634A0 (en) | 1993-02-15 | 1994-05-30 | Wellcome Found | Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them |
EP0646570B1 (en) | 1993-04-16 | 1998-06-24 | Shionogi & Co., Ltd. | Process for producing lignan compound |
TW289020B (xx) | 1993-05-08 | 1996-10-21 | Hoechst Sktiengesellschaft | |
TW289021B (xx) | 1993-05-08 | 1996-10-21 | Hoechst Ag | |
EP0624593A3 (de) | 1993-05-08 | 1995-06-07 | Hoechst Ag | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel. |
US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
IT1273751B (it) | 1994-02-11 | 1997-07-10 | Smithkline Beecham Farma | Derivati azaciclici |
ZA956647B (en) | 1994-08-10 | 1997-02-10 | Wellcome Found | Hypolipidaemic compounds. |
US5994391A (en) | 1994-09-13 | 1999-11-30 | G.D. Searle And Company | Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
PT781278E (pt) * | 1994-09-13 | 2001-08-30 | Monsanto Co | Novas benzotiepinas com actividade inibidora do transporte de acido biliar ileal e da remocao do taurocolato |
US5705524A (en) | 1994-11-04 | 1998-01-06 | Gilead Sciences, Inc. | Thiepane compounds |
US6034118A (en) | 1994-11-04 | 2000-03-07 | Gilead Sciences, Inc. | Thiepane compounds |
GB9423172D0 (en) | 1994-11-17 | 1995-01-04 | Wellcom Foundation The Limited | Hypolipidemic benzothiazepines |
WO1996040255A2 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist |
ES2150679T3 (es) | 1995-07-21 | 2000-12-01 | Nycomed Austria Gmbh | Derivados de bencenosulfonamidas como inhibidores de la enzima ciclooxigenasa ii. |
GB2305665A (en) | 1995-09-26 | 1997-04-16 | Merck & Co Inc | Selective ß3 agonists for the treatment of diabetes aand obesity |
DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
EP0801060A1 (en) | 1996-04-09 | 1997-10-15 | Pfizer Inc. | Heterocyclic Beta-3 Adrenergenic Agonists |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
IL129744A0 (en) * | 1996-11-27 | 2000-02-29 | Pfizer | Apo b-secretion/mtp inhibitory amides |
ATE242258T1 (de) | 1997-03-14 | 2003-06-15 | Aventis Pharma Gmbh | Hypolipidemische 1,4-benzothiazepin-1,1-dioxide |
JPH10287662A (ja) | 1997-04-08 | 1998-10-27 | Kitasato Inst:The | Fo−5637a物質及びb物質並びにそれらの製造法 |
US5929062A (en) | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
WO1999014204A1 (en) * | 1997-09-16 | 1999-03-25 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
GB2329334A (en) | 1997-09-18 | 1999-03-24 | Reckitt & Colmann Prod Ltd | Cholesterol-lowering agents |
EA005815B1 (ru) * | 1998-12-23 | 2005-06-30 | Джи.Ди.Сирл Ллс | Комбинация ингибиторов транспорта желчных кислот в подвздошной кишке и ингибиторов белка, переносящего эфиры холестерина, для сердечно-сосудистых показаний |
DE19916108C1 (de) * | 1999-04-09 | 2001-01-11 | Aventis Pharma Gmbh | Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung |
-
1999
- 1999-12-17 EA EA200100705A patent/EA005815B1/ru not_active IP Right Cessation
- 1999-12-17 BR BR9916486-8A patent/BR9916486A/pt not_active Application Discontinuation
- 1999-12-17 PL PL99348508A patent/PL348508A1/xx not_active Application Discontinuation
- 1999-12-17 WO PCT/US1999/027947 patent/WO2000038726A1/en not_active Application Discontinuation
- 1999-12-17 HU HU0201972A patent/HUP0201972A3/hu unknown
- 1999-12-17 KR KR1020017008085A patent/KR20010108046A/ko not_active Application Discontinuation
- 1999-12-17 EP EP03011146A patent/EP1342475A1/en not_active Withdrawn
- 1999-12-17 JP JP2000590677A patent/JP2002533412A/ja active Pending
- 1999-12-17 DK DK99965902T patent/DK1140188T3/da active
- 1999-12-17 PT PT99965902T patent/PT1140188E/pt unknown
- 1999-12-17 CZ CZ20012340A patent/CZ20012340A3/cs unknown
- 1999-12-17 MX MXPA01006471A patent/MXPA01006471A/es unknown
- 1999-12-17 CN CN99816268A patent/CN1342089A/zh active Pending
- 1999-12-17 US US09/466,415 patent/US6458851B1/en not_active Expired - Fee Related
- 1999-12-17 AT AT99965902T patent/ATE241386T1/de not_active IP Right Cessation
- 1999-12-17 AU AU21578/00A patent/AU776620B2/en not_active Ceased
- 1999-12-17 EP EP99965902A patent/EP1140188B1/en not_active Expired - Lifetime
- 1999-12-17 ES ES99965902T patent/ES2200587T3/es not_active Expired - Lifetime
- 1999-12-17 DE DE69908414T patent/DE69908414T2/de not_active Expired - Fee Related
- 1999-12-17 NZ NZ512536A patent/NZ512536A/en unknown
- 1999-12-17 CA CA002356422A patent/CA2356422C/en not_active Expired - Fee Related
- 1999-12-17 IL IL14394699A patent/IL143946A0/xx unknown
-
2001
- 2001-06-22 NO NO20013161A patent/NO20013161L/no not_active Application Discontinuation
-
2002
- 2002-04-10 HK HK02102732A patent/HK1041443A1/xx not_active IP Right Cessation
- 2002-07-23 US US10/200,599 patent/US20030203892A1/en not_active Abandoned
- 2002-08-22 HK HK02106168.1A patent/HK1044479A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DK1140188T3 (da) | 2003-09-29 |
CZ20012340A3 (cs) | 2001-11-14 |
NO20013161L (no) | 2001-08-17 |
DE69908414D1 (de) | 2003-07-03 |
AU2157800A (en) | 2000-07-31 |
EP1140188B1 (en) | 2003-05-28 |
NZ512536A (en) | 2003-11-28 |
CN1342089A (zh) | 2002-03-27 |
ATE241386T1 (de) | 2003-06-15 |
HK1041443A1 (en) | 2002-07-12 |
EP1140188A1 (en) | 2001-10-10 |
HK1044479A1 (zh) | 2002-10-25 |
US6458851B1 (en) | 2002-10-01 |
DE69908414T2 (de) | 2004-04-01 |
CA2356422A1 (en) | 2000-07-06 |
HUP0201972A2 (en) | 2002-10-28 |
CA2356422C (en) | 2008-09-16 |
US20030203892A1 (en) | 2003-10-30 |
WO2000038726A1 (en) | 2000-07-06 |
PT1140188E (pt) | 2003-10-31 |
PL348508A1 (en) | 2002-05-20 |
EA005815B1 (ru) | 2005-06-30 |
AU776620B2 (en) | 2004-09-16 |
HUP0201972A3 (en) | 2005-06-28 |
EA200100705A1 (ru) | 2002-02-28 |
JP2002533412A (ja) | 2002-10-08 |
EP1342475A1 (en) | 2003-09-10 |
ES2200587T3 (es) | 2004-03-01 |
KR20010108046A (ko) | 2001-12-07 |
BR9916486A (pt) | 2002-02-05 |
MXPA01006471A (es) | 2004-03-10 |
NO20013161D0 (no) | 2001-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL348508A1 (en) | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications | |
AU3103800A (en) | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications | |
MY121399A (en) | Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications | |
MXPA01006472A (es) | Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares. | |
BR9916484A (pt) | Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares | |
IL143949A0 (en) | Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications | |
AU2157500A (en) | Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications |